Cargando…

Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study

BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN AND SETTING: Retrospective study conducted in Atatürk Chest Diseases and Chest Surg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ergür, Figen Öztürk, Yıldız, Murat, Şener, Melahat Uzel, Kavurgacı, Suna, Ozturk, Ayperi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Paulista de Medicina - APM 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671260/ https://www.ncbi.nlm.nih.gov/pubmed/35507992 http://dx.doi.org/10.1590/1516-3180.2021.0489.R1.13082021

Ejemplares similares

Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia
por: Suna, Kavurgacı, et al.
Publicado: (2022)

Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia
por: Suna, Kavurgacı, et al.
Publicado: (2022)

Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study
por: Şener, Melahat Uzel, et al.
Publicado: (2022)

An unusual, life-threatening complication of EBUS-TBNA: Pneumoperitoneum
por: Söyler, Yasemin, et al.
Publicado: (2023)

Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
por: Tatar, Erhan, et al.
Publicado: (2020)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Toxic hepatitis case with prolonged jaundice due to Favipiravir
por: Yolacan, Ramazan, et al.
Publicado: (2022)

Imaging of COVID-19 pneumonia in children
por: Palabiyik, Figen, et al.
Publicado: (2020)

Safety of geriatric patients undergoing endobronchial ultrasound-guided transbronchial needle aspiration with deep sedation: a retrospective study
por: Tunç, Mehtap, et al.
Publicado: (2023)

Comparison of the International Classification of High-resolution Computed Tomography for occupational and environmental respiratory diseases with the International Labor Organization International Classification of Radiographs of Pneumoconiosis
por: ŞENER, Melahat Uzel, et al.
Publicado: (2018)

What is the yield of EBUS-TBNA for re-evaluation of previously treated non-small-cell lung cancer?
por: ÖZTÜRK, Ayperi, et al.
Publicado: (2023)

COVID‐19 pneumonia suspected to be co‐infection with Mycoplasma pneumoniae and improved by early administration of favipiravir and ciclesonide
por: Ito, Keima, et al.
Publicado: (2021)

Acute Psychosis in COVID-19: Is It Due to Favipiravir Treatment or Acute Viral Illness?
por: Duyan, Murat, et al.
Publicado: (2021)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database
por: Kaur, Rimple Jeet, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Contribution of (18)F-FDG PET/CT in the Differential Diagnosis of Pulmonary Hamartomas and Pulmonary Carcinoids
por: Tatcı, Ebru, et al.
Publicado: (2021)

Primary pulmonary meningioma mimicking pulmonary metastasis: A rare case report
por: Gürçay, Nesrin, et al.
Publicado: (2020)

Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
por: Alotaibi, Musim, et al.
Publicado: (2021)

Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19
por: Bayram, Mehmet, et al.
Publicado: (2021)

Chloroquine/favipiravir/rituximab: COVID-19-pneumonia, off-label use and lack of efficacy: case report
Publicado: (2022)

EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA
por: Delen, Leman Acun, et al.
Publicado: (2022)

Severe sinus bradycardia associated with favipiravir in a COVID‐19 patient
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Correlation of Pectoralis Muscle Volume and Density with Severity of COVID-19 Pneumonia in Adults
por: Hocaoglu, Elif, et al.
Publicado: (2021)

Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?
por: Öztürk, Selçuk, et al.
Publicado: (2020)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
por: Yamamura, Hitoshi, et al.
Publicado: (2020)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

Favipiravir exposure and pregnancy outcome of COVID-19 patients
por: Tırmıkçıoğlu, Zeynep
Publicado: (2022)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study
por: Almutairi, Amal Oweid, et al.
Publicado: (2023)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid
por: Shinoda, Masahiro, et al.
Publicado: (2021)

Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study
por: Almoosa, Zainab, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r996vv6o2mumfvo6b0vus62blk